Table 1.
Main baseline characteristics of patients
| Variables | All case (n=41) |
| Sex(male/female) | 22/19 |
| Age at diagnosis, n (%) | |
| A1 | 3 (7.3) |
| A2 | 22 (53.7) |
| A3 | 16 (39.0) |
| Follow-up time [month, median (IQR)] | 48 (24.0-120.0) |
| CDAI [score, median (IQR)] | 115.24 (90.15-148.74) |
| Extraintestinal manifestations (EIMs), n (%) | 11 (26.8) |
| Family history, n (%) | |
| No | 39 (95.1) |
| Family history of CRC or IBD | 0 (0) |
| Family history of other autoimmune disease | 2 (4.9) |
| History of surgery, n (%) | 23 (56.1) |
| Location of CD, n (%) | |
| L1 | 21 (51.2) |
| L2 | 7 (17.1) |
| L3 | 11 (26.8) |
| L4 | 2 (4.9) |
| Behavior of CD, n (%) | |
| B1 | 5 (12.2) |
| B2 | 27 (65.9) |
| B3 | 9 (22.0) |
| Mesalamine, n (%) | 27 (65.9) |
| Biologics, n (%) | 11 (26.8) |
| Steroids, n (%) | 13 (31.7) |
| Immunomodulators, n (%) | 14 (34.1) |
| Hb (g/L, mean ± SD) | 115.34±18.33 |
| Alb (g/L, mean ± SD) | 35.21±5.64 |
Age of diagnosis was divided into A1, A2 and A3 according to the Montreal classification. A1: before the age of 16; A2: age of 17 to 40; A3: over the age of 40.
IQR, Interquartile range; CRC, Colorectal cancer; IBD, Inflammatory bowel disease; Hb, hemoglobin; Alb, Albumin.